Calviri
[Closed for Investment] Calviri, with a valuation of $165.8 million, is raising funds on StartEngine. It is a pre-market biotech company that has built a vaccine to prevent cancer in dogs. Calviri has done several pre-clinical studies to create vaccines that prevent cancer from starting in the first place and has completed a 5-year trial in over 800 dogs. The company discovered neoantigens that are absent from healthy cells and shared among tumors of different dogs, and is seeking USDA approval for an improved vaccine to be launched in 2025. Stephen Albert Johnson and Kathryn F. Sykes founded Calviri in December 2015. The current crowdfunding campaign has a minimum target of $9,998.10 and a maximum target of $1.23 million. The campaign proceeds will be used for research and development, company employment, and operations.
Investment Overview
Raised: $0
Deal Terms
Total Commitments ($USD)
- Platform
- StartEngine
- Start Date
- 08/22/2024
- Close Date
- 10/24/2024
$9,998
$1,234,999
$499
Equity - Common
Pre-Seed
RegCF
$3.22
$165,816,666
Company & Team
Company
- Year Founded
- 2015
- Industry
- Healthcare & Pharmaceuticals
- Tech Sector
- Distribution Model
- B2B2C
- Margin
- Low
- Capital Intensity
- High
Upgrade to gain access
-
$12.50 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
Kingscrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Ratings 
Company Funding & Growth
Funding history
- Total Prior Capital Raised
- $24,000,000
- Grants
- $6,400,000
- VC Backed?
- No
| Close Date | Platform | Valuation | Total Raised | Security Type | Status | Reg Type |
|---|---|---|---|---|---|---|
| 10/24/2024 | StartEngine | $165,816,666 | $0 | Equity - Common | Not Funded | RegCF |